Skp Global Medicines Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 05-12-2024
- Paid Up Capital ₹ 1.50 Cr
as on 05-12-2024
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 7.00 Cr
as on 05-12-2024
- Revenue -73.48%
(FY 2023)
- Profit -247.09%
(FY 2023)
- Ebitda 16.60%
(FY 2023)
- Net Worth -1.28%
(FY 2023)
- Total Assets 224.42%
(FY 2023)
About Skp Global Medicines
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹7.00 Cr.
Ramesh Tupe, Kartiki Tupe, Manodnya Sapre, and One other member serve as directors at the Company.
- CIN/LLPIN
U33100PN2016PTC166968
- Company No.
166968
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Oct 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Skp Global Medicines?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramesh Tupe  | Director | 05-May-2021 | Current |
| Kartiki Tupe | Director | 04-May-2021 | Current |
| Manodnya Sapre | Director | 28-Sep-2022 | Current |
| Girish Jaiwal | Director | 28-Oct-2016 | Current |
Financial Performance of Skp Global Medicines.
Skp Global Medicines Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 73.48% decrease. The company also saw a substantial fall in profitability, with a 247.09% decrease in profit. The company's net worth dipped by a decrease of 1.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skp Global Medicines?
Unlock access to Skp Global Medicines's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Kings Global Biotech LimitedActive 8 years 6 monthsKartiki Tupe, Manodnya Sapre and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 22 Mar 2024 | ₹7.00 Cr | Open |
How Many Employees Work at Skp Global Medicines?
Unlock and access historical data on people associated with Skp Global Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skp Global Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skp Global Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
